Vanguard Group Inc. raised its stake in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 5.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,310,537 shares of the biotechnology company’s stock after buying an additional 396,678 shares during the period. Vanguard Group Inc. owned about 0.06% of ZIOPHARM Oncology worth $46,348,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Teachers Advisors LLC boosted its stake in shares of ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock worth $1,062,000 after buying an additional 3,699 shares during the last quarter. American International Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 7.1% in the first quarter. American International Group Inc. now owns 74,843 shares of the biotechnology company’s stock worth $475,000 after buying an additional 4,951 shares during the last quarter. Private Advisor Group LLC boosted its stake in shares of ZIOPHARM Oncology by 23.4% in the first quarter. Private Advisor Group LLC now owns 41,541 shares of the biotechnology company’s stock worth $260,000 after buying an additional 7,875 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of ZIOPHARM Oncology by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 598,406 shares of the biotechnology company’s stock worth $3,794,000 after buying an additional 9,652 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of ZIOPHARM Oncology by 5.5% in the first quarter. Wells Fargo & Company MN now owns 199,406 shares of the biotechnology company’s stock worth $1,264,000 after buying an additional 10,424 shares during the last quarter. Institutional investors own 38.20% of the company’s stock.

Shares of ZIOPHARM Oncology Inc (ZIOP) traded up 1.10% during mid-day trading on Friday, hitting $5.51. The stock had a trading volume of 1,532,563 shares. The firm’s market cap is $774.88 million. The company has a 50-day moving average of $5.93 and a 200 day moving average of $6.33. ZIOPHARM Oncology Inc has a one year low of $4.84 and a one year high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. During the same period in the previous year, the company earned ($1.01) earnings per share. The business’s revenue for the quarter was down 5.9% on a year-over-year basis. On average, equities research analysts forecast that ZIOPHARM Oncology Inc will post ($0.54) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/12/ziopharm-oncology-inc-ziop-position-boosted-by-vanguard-group-inc.html.

A number of analysts have recently issued reports on the company. ValuEngine upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Zacks Investment Research upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. HC Wainwright set a $10.00 target price on ZIOPHARM Oncology and gave the stock a “buy” rating in a report on Tuesday, August 1st. Finally, BidaskClub upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. ZIOPHARM Oncology currently has a consensus rating of “Hold” and a consensus price target of $13.17.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.